meant to say 'they' are a competitor in some markets. Go to CSCs website and look under insurance. This would certainly be a nice acquisition for them IMO
This is how you address the coordinated short attacks. This puts a floor under it. Hopefully others suitors will look to pay more. The only downside to beating the coordinated short effort is that the company will no longer be a publicly traded company.
DJ Moody's Downgrades J.C. Penney's Cfr To Caa1; Outlook Remains Negative
Moody's Cites Near Term Significant Weakness In JCP's Operating Performance,Credit Metric
J.C. Penney's Speculative Grade Liquidity Rating Of SGL-3 Remains Unchanged
Moody's: JCP Is In Process Of Readdressing Its Operating Strategies Which Will Likely Result In Earnings Remaining Weak Next Few Quarters
Moody's J.C. Penney's Earnings Continue to Face Downward Pressure Until Co. Stabilizes Sales, Gross Margin Trend
Yes it was. Very solid company. Never know how share price will move in this market but all the elements are there to support a much higher share price.
Jefferies cautious on VIVUS after FDA expands Qsymia distribution
Jefferies believes retail distribution of Qsymia will not materially accelerate patient demand and says it remains cautious on shares of VIVUS. The firm keeps an Underperform rating on the stock with a $5 price target.
From Monday 4/15 Equities research analysts at Deutsche Bank boosted their price target on shares of Rose Rock Midstream (NASDAQ: RRMS) from $39.00 to $44.00 in a research note issued to investors on Monday, AnalystRatingsNetwork reports. The firm currently has a “buy” rating on the stock.
RRMS has been the subject of a number of other recent research reports. Analysts at Morgan Stanley initiated coverage on shares of Rose Rock Midstream in a research note to investors on Wednesday, April 10th. They set an “equal weight” rating and a $42.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Rose Rock Midstream from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, April 3rd. They now have a $39.40 price target on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of Rose Rock Midstream from $33.00 to $38.00 in a research note to investors on Tuesday, March 5th. They now have a “neutral” rating on the stock.
Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $39.06.